CG Oncology (NASDAQ:CGON) Price Target Raised to $96.00

CG Oncology (NASDAQ:CGON) had its target price increased by investment analysts at JPMorgan Chase & Co. from $91.00 to $96.00 in a report issued on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 39.30% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. Truist Financial reiterated a “buy” rating and set a $77.00 price target (up from $75.00) on shares of CG Oncology in a report on Monday. Royal Bank Of Canada boosted their price target on shares of CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a report on Monday. Wall Street Zen cut shares of CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. HC Wainwright boosted their price target on shares of CG Oncology from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Finally, Wedbush boosted their price target on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, CG Oncology has a consensus rating of “Moderate Buy” and an average price target of $81.27.

CG Oncology Price Performance

Shares of CGON stock traded down $0.71 during trading on Monday, reaching $68.92. The company’s stock had a trading volume of 344,701 shares, compared to its average volume of 1,226,061. The company has a market capitalization of $6.07 billion, a price-to-earnings ratio of -29.58 and a beta of 0.41. The stock’s 50-day moving average price is $65.66 and its 200 day moving average price is $52.87. CG Oncology has a 1-year low of $23.32 and a 1-year high of $73.56.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The company had revenue of $1.08 million for the quarter, compared to analysts’ expectations of $0.45 million. On average, sell-side analysts anticipate that CG Oncology will post -2.56 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director James Mulay sold 15,600 shares of the company’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $73.01, for a total value of $1,138,956.00. Following the completion of the sale, the director owned 15,600 shares in the company, valued at $1,138,956. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.80% of the stock is currently owned by company insiders.

Institutional Trading of CG Oncology

Several institutional investors and hedge funds have recently bought and sold shares of CGON. AQR Capital Management LLC purchased a new stake in CG Oncology in the 1st quarter valued at $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in CG Oncology by 18.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock worth $876,000 after buying an additional 5,442 shares during the last quarter. Millennium Management LLC raised its position in CG Oncology by 139.4% during the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock worth $14,597,000 after buying an additional 347,055 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in CG Oncology by 42.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock worth $4,393,000 after buying an additional 53,461 shares during the last quarter. Finally, Legal & General Group Plc raised its position in CG Oncology by 12.3% during the 2nd quarter. Legal & General Group Plc now owns 44,354 shares of the company’s stock worth $1,153,000 after buying an additional 4,847 shares during the last quarter. Hedge funds and other institutional investors own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.